Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Radmd LLC

Neither a doctor nor a teaching hospital

Research payments

$1,100,845

397 payments

Through program year 2025, Radmd LLC is reported as receiving $1,100,845 in research payments, across 397 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $191,511 49
2024 Research $187,978 90
2023 Research $127,078 80
2022 Research $87,051 66
2021 Research $279,771 85
2020 Research $93,020 16
2019 Research $134,437 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $263,021 39 payments
  2. GlaxoSmithKline, LLC. $255,790 55 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $120,685 76 payments
  4. Acerta Pharma LLC $91,226 9 payments
  5. F. Hoffmann-La Roche AG $83,671 4 payments
  6. AstraZeneca Pharmaceuticals LP $77,435 1 payment
  7. MorphoSys AG $57,226 71 payments
  8. EMD Serono, Inc. $46,919 23 payments
  9. BioNTech SE $27,601 46 payments
  10. H. Lundbeck A S $21,518 21 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter S $150,808 35 payments
  2. Study name not reported $94,857 12 payments
  3. A Phase 3 Randomized Open-Label Study of Brigatinib (Alunbrig?) Versus Alectinib (Alecensa?) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori?) $91,845 19 payments
  4. A Phase 1 First in Human Multicenter Open-label Doseescalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab Oleclumab in Advanced Solid Tumors $77,435 1 payment
  5. Abt 199 GDC 0199 in 1L Dlbcl $76,058 1 payment
  6. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $56,111 10 payments
  7. A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) - B-MIND $46,288 41 payments
  8. A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy $45,084 18 payments
  9. A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL $40,290 1 payment
  10. Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy $36,344 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $788 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record